Described herein are compositions of hydrogels and methods of use thereof.

The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

A method for manufacturing a fibrinogen preparation from a fibrinogen containing source derived from blood plasma includes providing a liquid phase containing plasmatic fibrinogen; contacting the liquid phase with a cation exchange chromatography material under conditions resulting in binding of fibrinogen, wherein the liquid phase has a pH in the range of pH 5.6 to pH 7.0 which is near or above the pl of fibrinogen; optionally washing unbound compounds from the cation exchange chromatography material; and eluting the fibrinogen from the cation exchange material. The method is also suitable for reduction of von-Willebrand-factor.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.

Compositions comprised of: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one temperature in the range of 10° C., to 37° C., are disclosed herein. Methods for preparing a fibrin adhesive sealant in/on an injured tissue are further disclosed.

Compositions comprised of: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one temperature in the range of 10° C., to 37° C., are disclosed herein. Methods for preparing a fibrin adhesive sealant in/on an injured tissue are further disclosed.

Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of fractionation that utilize a combination of salt and organic solvent. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.